- Home
- MLYS vs APLS Comparison
MLYS vs APLS Comparison
Compare MLYS & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- APLS
- Stock Information
- Founded
- MLYS 2019
- APLS 2009
- Country
- MLYS United States
- APLS United States
- Employees
- MLYS N/A
- APLS N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- APLS Health Care
- Exchange
- MLYS Nasdaq
- APLS Nasdaq
- Market Cap
- MLYS 3.1B
- APLS 2.9B
- IPO Year
- MLYS 2023
- APLS 2017
- Fundamental
- Price
- MLYS $40.00
- APLS $28.21
- Analyst Decision
- MLYS Strong Buy
- APLS Buy
- Analyst Count
- MLYS 6
- APLS 19
- Target Price
- MLYS $42.60
- APLS $33.63
- AVG Volume (30 Days)
- MLYS 1.3M
- APLS 2.4M
- Earning Date
- MLYS 11-10-2025
- APLS 10-30-2025
- Dividend Yield
- MLYS N/A
- APLS N/A
- EPS Growth
- MLYS N/A
- APLS N/A
- EPS
- MLYS N/A
- APLS N/A
- Revenue
- MLYS N/A
- APLS $754,649,000.00
- Revenue This Year
- MLYS N/A
- APLS $24.62
- Revenue Next Year
- MLYS N/A
- APLS N/A
- P/E Ratio
- MLYS N/A
- APLS N/A
- Revenue Growth
- MLYS N/A
- APLS 20.02
- 52 Week Low
- MLYS $8.24
- APLS $16.10
- 52 Week High
- MLYS $44.80
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- MLYS 53.93
- APLS 64.41
- Support Level
- MLYS $41.74
- APLS $23.85
- Resistance Level
- MLYS $44.60
- APLS $25.73
- Average True Range (ATR)
- MLYS 2.22
- APLS 1.28
- MACD
- MLYS -0.83
- APLS 0.51
- Stochastic Oscillator
- MLYS 46.44
- APLS 87.59
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.